摘要
目的 :探讨氯沙坦对糖尿病肾病肾脏功能的保护作用。方法 :制作糖尿病大鼠模型 ,分成 3组 ,每组 15只 ,糖尿病治疗组给予氯沙坦灌胃 ,糖尿病组和正常对照组均给予等量生理盐水灌胃。分别于实验的wk 1,2 ,4取材 ,测定血糖、血肌酐、尿清蛋白、尿肌酐、尿α1 微球蛋白排泄率和血浆内皮素(ET)水平。结果 :糖尿病组大鼠出现血糖升高、肌酐清除率下降、尿清蛋白和尿α1 微球蛋白排泄率升高 ,与正常对照组相比差异有非常显著和显著意义(P <0 .0 1或P <0 .0 5 ) ,血浆ET水平升高 ,wk 2时与正常对照组间差异有非常显著意义 ;肌酐清除率、尿清蛋白和尿α1 微球蛋白排泄率等指标 ,治疗组与糖尿病组比较差异均有显著或非常显著意义。结论 :动物实验证实氯沙坦可减轻糖尿病肾病的肾功能损害 ,改善肾功能 。
AIM: To investigate the renoprotective effect of losartan, an angiotensin Ⅱ 1 type receptor antagonist (AT 1Ra), on diabetic nephropathy. METHODS: The diabetic model of rats were designed and divided into three groups: diabetic treatment group, diabetic group and control group. The diabetic treatment group was treated with losartan, diabelic group and control group were treated with saline. After 1,2 and 4 wk respectively, the animals were killed for the measurements of urine albumine excretion rate (UAER), creatinine clearance (Ccr), endothelin (ET), α 1-microglobulin excretion (α 1-MG) and blood glucose. RESULTS: In the untreated diabetic rats, blood glucose was increased, wheras Ccr decreased. Moreover, UAER and α 1-MG were elevated over 4 wk period of study with a very significant difference or significant difference between the treatment and control groups (P<0.01). The diabetic group had a increased level of ET at the wk 2 and it was very significantly different from that of the controls (P<0.01). Concerning Ccr, UAER and α 1-MG, there were very significant or significant differences between the treatment and diabetic groups (P<0.01, or P<0.05). CONCLUSION: The present study found that losartan could definitely inhibit the functional abnormalities in diabetic nephropathy and had a renoprotection.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2002年第9期547-550,共4页
Chinese Journal of New Drugs and Clinical Remedies
